Viewing nowCombinationHyusigaduo Extended-Release Tablet 10/500 mg (Dapagliflozin, Metformin)
Metformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
Hyuons Co., Ltd.

MFDS item code 202300359 · Approved 2023.01.27 · Insurance code 670402390,670609300
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication helps improve blood sugar control in adult patients with type 2 diabetes by using dapagliflozin and metformin together. It is used in conjunction with dietary and exercise regimens to enhance blood sugar control. It can be used in patients with type 2 diabetes who have insufficient blood sugar control and have cardiovascular disease or risk factors. However, please refer to professional information for effects on the occurrence of cardiovascular events. This medication is effectively used for the treatment of type 2 diabetes.
The dose of this medicine should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior antidiabetic drug treatment for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior antidiabetic drug treatment, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medicine should provide the patient’s current dose of metformin or the nearest appropriate therapeutically equivalent dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue, such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other antihyperglycemic agents. Because changes may cause alterations in glycemic control, any change in treatment for patients with type 2 diabetes should be made under close monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other condition that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).
This medication is used in the treatment of diabetes, with the main ingredients being dapagliflozin and metformin. It should not be used in patients with impaired kidney function or certain serious diseases. This medication can very rarely cause a serious side effect known as lactic acidosis, so particular caution is needed in cases of impaired kidney or liver function. Lactic acidosis is a condition characterized by excessive accumulation of lactic acid in the body, with symptoms that may include fatigue, muscle pain, shortness of breath, and abdominal pain. Additionally, there is a risk of hypoglycemia when this medication is used with other antidiabetic drugs or insulin, so blood glucose levels should be monitored frequently, and dosages adjusted as needed. This medication can cause dehydration or low blood pressure; patients with a reduced volume of fluid or low blood pressure should consult a physician before administration. Special caution is needed for the elderly or patients taking diuretics. Genital or urinary infections may occur; if related symptoms arise, notify healthcare providers immediately. Furthermore, this medication may lower vitamin B12 levels, so regular checks of vitamin B12 levels are recommended during long-term use. Pregnant or breastfeeding women should not use this medication, and if pregnancy is planned or confirmed, they must inform their physician. Prior to surgery or contrast examinations, this medication should be discontinued for a specified period, and it should be restarted only after confirming normal kidney function. In cases of overdose, serious side effects can occur, so it is essential to adhere strictly to the prescribed regimen and dosages. Finally, alcohol intake should be avoided during the use of this medication, and caution should be exercised as dizziness and other symptoms may occur during driving or operating machinery.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. The recommended storage temperature is between 1 to 30 degrees Celsius at room temperature. This way, the drug's effectiveness and safety can be maintained for an extended period.
Pink, double-convex, rectangular extended-release film-coated tablet
Bottle - 30 tablets per bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
Hyuons Co., Ltd.
Metformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
Metformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
YouYoung Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
Yuyoung Pharmaceutical Co., Ltd.
CombinationDapagliflozin Propanediol Hydrate 12.3mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Aju Pharmaceuticals Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.